Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 33

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 33
---
 Common Stock, 
 with an exercise price of $38.50 per share;                                                                   |

| • |     | 34,286 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with 
 an exercise price of $43.75 per share;                                                                            |

| • |     | 319,132 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, 
 with a current exercise price of $36.40 per share;                                                            |

| • |     | 914,823 shares of Common Stock issuable upon conversion of the senior secured convertible notes, with a current 
 conversion price of $36.40 per share;                                                                           |

| • |     | 1,642,871 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, 
 with an exercise price of $22.72 per share;                                                                     |

| • |     | 131,472 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, 
 with an exercise price of $25.81 per share; and                                                               |

| • |     | 3,250,000 shares of Common Stock, issuable upon the exercise of the warrants to purchase shares of Common Stock, 
 with an exercise price of $1.20 per share.                                                                       |

22

RISK FACTORS Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled “Cautionary Note Regarding Forward-Looking Statements”. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. Risks Related to our Limited Operating History, Financial Condition and Capital Requirements We currently have three commercial products, ZTlido, ELYXY